Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Vermillion Taps McLain for CEO

Premium

Vermillion has appointed Thomas McLain as president and CEO. He replaces Bruce Huebner, who has served as interim CEO since last November when he took over for Gail Page.

Huebner will remain a director of the company.

Prior to joining Vermillion, McLain served as CEO and CFO of Claro Scientific. Before that, he held senior management positions at Nabi Biopharmaceuticals (now Biota Pharmaceuticals) and Bausch & Lomb. He has also served on the boards of Eastman Chemical, and the Biotechnology Industry Organization.

He holds an MBA in accounting and information systems from the University of Rochester, Simon Graduate School of Business, and a BA in economics from the College of the Holy Cross.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.